Cytek Biosciences, Inc. - CTKB
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Boston Partners | 6.16% | 8,002,638 | View |
| Nov 03, 2026 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 4.5% | 5,870,954 | View |
| Nov 03, 2026 | SCHEDULE 13G/A | Millennium Management LLC | 5.6% | 7,281,488 | View |
| Nov 03, 2026 | SCHEDULE 13G/A | Millennium Group Management LLC | 5.6% | 7,281,488 | View |
| Nov 03, 2026 | SCHEDULE 13G/A | Israel A. Englander | 5.6% | 7,281,488 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 5.5% | 7,162,923 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | Millennium Management LLC | 7.2% | 9,338,010 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | Millennium Group Management LLC | 7.2% | 9,338,010 | View |
| Aug 06, 2026 | SCHEDULE 13G/A | Israel A. Englander | 7.2% | 9,338,010 | View |
| Aug 04, 2026 | SCHEDULE 13G | Boston Partners | 5.91% | 7,635,145 | View |
| Jul 08, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 7.2% | 9,356,551 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.